The function of PKN, a stress-activated protein kinase, in the heart is poorly understood. Objective: We investigated the functional role of PKN during myocardial ischemia/reperfusion (I/R). Methods and Results: PKN is phosphorylated at Thr774 in hearts subjected to ischemia and reperfusion. Key Words: ischemia/reperfusion Ⅲ PKN Ⅲ ␣ B crystallin Ⅲ proteasome A lthough myocardial ischemia and reperfusion induce lethal injury in the heart, the heart and the cardiac myocytes therein have powerful endogenous mechanisms to protect themselves from energy deficiency, oxidative stress, protein aggregation, and organelle malfunction, thereby minimizing myocardial injury. 1 Ischemic preconditioning is one of the strongest of these endogenous mechanisms of cardioprotection, and pharmacological intervention mimicking the ischemic preconditioning effect is considered to be a promising modality for the treatment of ischemic heart disease. 1 However, other endogenous mechanisms of cardioprotection activated during ischemia and reperfusion remain to be elucidated.
A lthough myocardial ischemia and reperfusion induce lethal injury in the heart, the heart and the cardiac myocytes therein have powerful endogenous mechanisms to protect themselves from energy deficiency, oxidative stress, protein aggregation, and organelle malfunction, thereby minimizing myocardial injury. 1 Ischemic preconditioning is one of the strongest of these endogenous mechanisms of cardioprotection, and pharmacological intervention mimicking the ischemic preconditioning effect is considered to be a promising modality for the treatment of ischemic heart disease. 1 However, other endogenous mechanisms of cardioprotection activated during ischemia and reperfusion remain to be elucidated.
PKN, also known as protein kinase C-related kinase 1 (PRK1), is a serine (Ser)/threonine (Thr) kinase, with a molecular mass of 120 kDa. 2 PKN consists of a catalytic domain highly homologous to that of protein kinase (PK)C in the carboxyl-terminal region and a regulatory domain in the amino-terminal region. 2 PKN localizes primarily in the cytosolic fraction and possesses a wide variety of functions, such as cytoskeletal regulation, cell adhesion, vesicle transport, and cell cycle regulation, 3 and it has been shown to be involved in the pathogenesis of Alzheimer's disease 4 and amyotrophic lateral sclerosis. 5 Interestingly, PKN is cleaved by caspase 3, 6 and a truncated and kinase-active form of PKN has been found in ischemia/reperfusion (I/R) models of the rat retina 7 and brain, 8 suggesting that PKN may modulate cell survival or death during I/R. Transgenic (Tg) mice overexpressing a constitutively active (CA) form of PKN in mammary epithelium exhibit impaired tight junction sealing and increased apoptosis, resulting in precocious involution in the mammary gland. 9 PKN activates atrial natriuretic factor gene expression in cardiac myocytes. 10 However, the in vivo function of PKN is poorly understood in the heart. Thus, a major goal in this study was to elucidate the function of PKN in the heart in vivo. Our preliminary studies indicated that PKN is activated by stress, such as hypotonic stress and I/R. Therefore, we examined the role of PKN in regulating cell survival and death and myocardial injury in response to I/R and the underlying molecular mechanisms mediating the action of PKN in cardiac myocytes. Our results suggest that activation of PKN is an endogenous mechanism of cardioprotection against I/R injury.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org. All animal protocols were approved by the review board of the Institutional Animal Care and Use Committee of the University of Medicine and Dentistry of New Jersey.
PKN Kinase Assay
Cardiac myocyte lysates were prepared in lysis buffer containing 20 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1% IGEPAL CA-630, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L ␤glycero-phosphate, 0.1 mmol/L Na 3 VO 4 , 1 mmol/L NaF, 50 mol/L phenylmethylsulfonyl fluoride, 5 g/mL aprotinin, and 5 g/mL leupeptin. PKN was immunoprecipitated with PKN antibody (BD Transduction Laboratories) at 4°C for 120 minutes. Protein G Sepharose beads were added and incubated at 4°C for 50 minutes. After washing 3 times, the precipitates were incubated for 30 minutes at 30°C with reaction buffer containing 20 mmol/L Tris-HCl (pH7.5), 4 mmol/L MgCl 2 , 20 mol/L ATP, and 0.8 Ci [␥-
32 P]ATP and with 40 mol/L PKC␦ peptide (AMFPTMNRRG-SIKQAKI) as a peptide substrate. Incorporation of 32 P into the substrate was measured by scintillation counting.
Generation of Tg-CAPKN and Tg-DNPKN Mice
Transgenic mice with cardiac-specific overexpression of CAPKN 6 (amino acids 561 to 942) and DNPKN (full-length K644D 3 ) were generated on an FVB background using the ␣-myosin heavy chain promoter (courtesy of Dr J Robbins, Children's Hospital, Cincinnati, Ohio).
Construction of Short Hairpin RNA Adenoviral Expression Vectors
The U6 RNA polymerase III promoter and the polylinker region were subcloned into the adenoviral shuttle vector pDC311 (Microbix). The hairpin-forming oligo 5Ј-GATTGACATCATCCGCATGTTCAAGAGA-CATGCGGATGATGTCAATC-3Ј from the rat PKN cDNA and its antisense and the hairpin-forming oligo 5Ј-ACGTGGATCCTCTC-ACCATTATTCAAGAGATAATGGTGAGAGGATCCACGT-3Ј from the rat ␣ B crystallin (BC) cDNA and its antisense with ApaI and HindIII overhangs were synthesized, annealed, and subcloned distal to the U6 promoter. The loop sequence is underlined. A recombinant adenovirus was generated as described. 11
Statistics
All data are expressed as meansϮSEM. Differences between experimental groups were evaluated for statistical significance using Student t test for unpaired data or 1-way ANOVA, followed by Dunnett's post test when appropriate. Probability values of Ͻ0.05 were considered to be statistically significant.
Results

PKN Is Activated by I/R in the Heart
We examined whether PKN was activated in the heart under stress conditions, using a myocardial I/R model. In hearts subjected to ischemia, Thr774 phosphorylation of PKN was observed after 15 to 30 minutes and declined after 45 minutes ( Figure 1A and 1B). After reperfusion, PKN phosphorylation was observed again, and this phosphorylation was sustained for Ͼ24 hours ( Figure 1A and 1B) . In the hearts of sham-operated mice, expression and phosphorylation of PKN were unchanged over the entire experimental period (Online Figure I ).
CAPKN Transgenic Mice Show Cardiac Hypertrophy Without Cardiac Dysfunction
To elucidate the role of PKN activation in the in vivo heart, we generated mice with cardiac-specific expression of constitutively active PKN (Tg-CAPKN), using the ␣MHC promoter. In Tg-CAPKN mouse hearts, phosphorylation of endogenous PKN was increased 5-fold compared to in nontransgenic (NTg) hearts (Figure 2A ). Heart weight/body weight (HW/BW) and left ventricular (LV) weight/BW were significantly higher in Tg-CAPKN than in NTg mice at both 3 and 6 months old (Online Table I ). Lung weight/BW was not different between Tg-CAPKN and NTg mice (Online Table I ). LV cardiac myocyte cross-sectional area was significantly greater in Tg-CAPKN mice than in NTg mice ( Figure 2B and 2C). The echocardiographic parameters in Tg-CAPKN mice were normal except that the wall thickness was significantly greater in Tg-CAPKN mice than in NTg mice at both the ages of 3 and 6 months (Online Table II ). The end-diastolic diameter and end-systolic diameter were similar in both Tg-CAPKN and NTg mice, and the fractional shortening and the ejection fraction were also comparable (Online Table II ). Doppler analysis showed that the E/A ratio and deceleration time, indexes of diastolic function, were comparable in Tg-CAPKN and NTg mice (Online Figure II) . In Tg-CAPKN mice, the heart rate was slower by 10% compared to NTg mice (Online Table II ). Taken together, these data indicate that Tg-CAPKN mice showed LV hypertrophy without LV dysfunction.
We also generated transgenic mice with cardiac-specific overexpression of dominant negative (DN) PKN (Tg-DNPKN). The baseline cardiac phenotype of Tg-DNPKN was normal (Online Tables III and IV) .
Tg-CAPKN and NTg mice at 3 months old were subjected to 45 minutes of ischemia and 24 hours of reperfusion. The area at risk (AAR) was similar in Tg-CAPKN and NTg mice. The infarct size/AAR (MI/AAR) was significantly smaller in Tg-CAPKN than in NTg mice (15.1Ϯ5.2 versus 37.5Ϯ4.9%, PϽ0.01; Figure 3A through 3C). There were also fewer TUNEL-positive cells in the AAR in Tg-CAPKN than in NTg mice (0.3Ϯ0.2 versus 1.0Ϯ0.2%, PϽ0.05; Figure 3D and 3E). Furthermore, in Langendorff-perfused heart preparations, LV developed pressure and LV dP/dt were higher, and LV end-diastolic pressure was lower in Tg-CAPKN mice during the recovery phase after 45 minutes of global ischemia (Online Figure III) . These results suggest that activation of PKN is protective against I/R injury.
It should be noted that the heart rate was slower by 10% to 15% in Tg-CAPKN mice than in NTg mice. To test the possibility that the reduced heart rate alone could be the mechanism of cardioprotection in the Tg-CAPKN heart, we reduced the heart rate in the NTg mice to the same level as that in Tg-CAPKN mice using propranolol, a ␤-blocker, during the ischemia and early reperfusion periods. Although intraperitoneal injection of propranolol (3 mg/kg) reduced the heart rate in NTg to a similar level as that in Tg-CAPKN mice, MI/AAR was still significantly smaller in Tg-CAPKN than in NTg (Online Figure IV) , suggesting that lowering the heart rate alone in NTg mice is not sufficient to achieve the infarct reducing effect observed in Tg-CAPKN mice.
I/R Injury Is Enhanced in Tg-DNPKN Mice
To elucidate the role of endogenous PKN in mediating protection against I/R injury, we also conducted I/R in Tg-DNPKN mice. Activation of PKN in response to I/R was abolished in Tg-DNPKN (data not shown; see also Figure  6E ). In the DNPKN heart, MI/AAR (62.5Ϯ9.3 versus 45.2Ϯ8.4%, PϽ0.05) and the number of TUNEL-positive cells (7.9Ϯ1.0 versus 1.3Ϯ0.9%, PϽ0.05) were both greater than in NTg mice ( Figure 4A through 4F), indicating that activation of endogenous PKN is protective during I/R.
Activation of PKN Attenuates, Whereas Inactivation of PKN Enhances Death of Cardiac Myocytes in Response to Hydrogen Peroxide Stimulation In Vitro
To evaluate whether the protective effect of PKN is cellautonomous in cardiac myocytes, we conducted in vitro experiments, using cultured cardiac myocytes and adenovirus vectors harboring PKN (Ad-PKN), DNPKN (Ad-DNPKN), or short hairpin (sh)RNA-PKN (Ad-sh-PKN) (Online Figure  V) . Oxidative stress is one of the most important causes of I/R injury in the heart. To evaluate the role of PKN in mediating cell survival and death in response to oxidative stress, cardiac myocytes were transduced with Ad-PKN, Ad-DNPKN, or Ad-sh-PKN and then treated with hydrogen peroxide (H 2 O 2 ). Treatment with H 2 O 2 induced PKN Thr774 phosphorylation in cardiac myocytes ( Figure 5A ). Transduction of Ad-PKN reduced ( Figure 5B), whereas that of Ad-DNPKN or Ad-sh-PKN enhanced ( Figure 5C and 5D), cell death. These results suggest that activation of endogenous PKN during oxidative stress is protective and that the cell-protective effect of PKN is cell-autonomous.
Activation of PKN Causes Phosphorylation and Translocation of ␣BC Into the Cytoskeletal Fraction
␣BC, a member of the small heat shock protein family of molecular chaperones, has a cell-protective effect against stresses. 12 PKN upregulates ␣BC gene expression in HeLa S3 cells. 13 To address the molecular mechanism mediating the cell-protective effect of PKN in cardiac myocytes, we evaluated expression of total and phosphorylated forms of ␣BC. The level of total ␣BC was not different between Tg-CAPKN and NTg hearts ( Figure 6A ; Figure VI, A) . However, the level . ␣BC translocates to the cytoskeletal fraction and interacts with cytoskeletal proteins in response to stress, 14 thereby playing a protective role in the heart. 15 Translocation of ␣BC from the cytosol to the cytoskeletal fraction was also increased in Tg-CAPKN mice ( Figure 6B ). In addition to Ser59 phosphorylation, Ser45 phosphorylation of ␣BC and its translocation to the cytoskeletal fraction were also increased in Tg-CAPKN mice ( Figure  6C and 6D; Online Figure VI, G). In hearts subjected to I/R, both Ser45 and Ser59 phosphorylation of ␣BC and its translocation to the cytoskeletal fraction were increased (Online Figure VII) . The increase in ␣BC phosphorylation at both Ser45 and Ser59 in response to I/R was markedly inhibited in Tg-DNPKN mice ( Figure 6E ). These results suggest that PKN plays an important role in mediating phosphorylation of ␣BC, which may in turn mediate protective effects in the heart during I/R. To address the role of ␣BC in mediating the cell-protective effect of PKN, we knocked down ␣BC by shRNA and examined the cell viability under H 2 O 2 treatment in cultured cardiac myocytes. Ad-sh-␣BC inhibited the cell-protective effect of PKN, indicating that ␣BC mediates the cell-protective effect of PKN ( Figure 6F ).
PKN Increases Proteasome Activity
Phosphorylation of ␣BC is important for its chaperone activity, 16 which in turn plays an important role in regulating protein quality control via the ubiquitin-proteasome system. We therefore evaluated proteasome activity in Tg-CAPKN mice and cardiac myocytes treated with Ad-PKN. The proteasome activity, as evaluated by chymotrypsin-like activity, was significantly elevated in Tg-CAPKN hearts compared to NTg hearts ( Figure  7A ). Similarly, cardiac myocytes transduced with Ad-PKN exhibited greater chymotrypsin-like activities than Ad-LacZtransduced myocytes (data not shown). In hearts subjected to I/R, chymotrypsin-like activity was decreased, an effect that was significantly attenuated in Tg-CAPKN hearts ( Figure 7B ). Furthermore, the decrease in chymotrypsin-like activity in response to I/R was significantly enhanced in Tg-DNPKN hearts ( Figure  7C ). To test the functional significance of the elevated proteasome activity in Tg-CAPKN hearts, the effect of epoxomicin, a proteasome inhibitor, on the cardioprotective effect of CAPKN was evaluated. Epoxomicin partially attenuated the infarctreducing effect in Tg-CAPKN mice ( Figure 7D ). These results are consistent with the notion that the elevated proteasome activity in Tg-CAPKN may, in part, mediate the protective effect against I/R. 
Discussion
Our main findings in this work are (1) that PKN is activated by I/R in the heart in vivo and by oxidative stress in cardiac myocytes in vitro; (2) that activation of PKN causes cardiac hypertrophy without LV dysfunction; (3) that activation of PKN plays a cell-protective role in cardiac myocytes during I/R in vivo and in response to oxidative stress in vitro; and (4) that PKN mediates its protective effects against I/R, in part, through activation of the ␣BC/proteasome pathway.
In our study, Thr774 phosphorylation of PKN, which is essential for its activation, was observed in hearts subjected to I/R in vivo. In yeast, Pkc1, whose amino-terminal regulatory region is highly homologous to that of PKN, is activated by cell wall stress, including hypotonic stress. 17 Pkc1 is also important for cell viability in the adaptive response to oxidative stress 18, 19 or nitrosative stress. 19 I/R causes both oxidative and osmotic stress, both of which affect survival and death of cardiac myocytes in the heart. 20,21 PKN is phosphorylated by H 2 O 2 in cardiac myocytes in vitro, and PKN phosphorylation caused by I/R is inhibited in the presence of MPG, an antioxidant, in the heart in vivo (Online Figure VIII) , suggesting that oxidative stress plays an important role in mediating I/R-induced PKN activation. Furthermore, we found previously that hypotonic stress causes activation of PKN in vitro (K.K. and J.S., manuscript in preparation). Thus, we speculate that osmotic stress may also mediate PKN activation in response to I/R. Interestingly, RhoA, a known activator of PKN, 3 is activated by reactive oxygen species. 22 Oxygen radicals can stimulate PKC directly by oxidative modification of its regulatory domain. 23 The role of RhoA and oxidative posttranslational modification of PKN in mediating activation of PKN during I/R remains to be elucidated.
Our findings suggest that activation of PKN in cardiac myocytes is necessary and sufficient for cardioprotection during I/R in vivo and in response to H 2 O 2 in vitro. Although LV function in Tg-DNPKN mice was comparable to that in NTg mice at 3 months of age, nearly complete downregulation of PKN by Ad-sh-PKN induces cell death in cardiac myocytes in vitro (Online Figure IX ), suggesting that a low level of PKN is required for survival of cardiac myocytes. Thus, all lines of experimental evidence presented in this work support the notion that PKN promotes survival of cardiac myocytes. Because PKN reduces the number of TUNEL-positive myocytes in the ischemic area after I/R, we speculate that the protective effect of PKN is mediated through suppression of apoptosis, but its effect on other forms of cell death remains to be elucidated.
Because suppression of myocardial injury during I/R was exacerbated when activation of PKN was inhibited in Tg-DNPKN mice, activation of PKN during I/R protects the heart. However, because Tg-CAPKN mice have stronger and more persistent activation of PKN, the cardioprotective effect observed in Tg-CAPKN may also be mediated, in part, by preconditioning effects. Our preliminary results suggest that PKN is also activated by preconditioning (data not shown). Whether or not activation of endogenous PKN can achieve protection against prolonged ischemia or late preconditioning remains to be elucidated. Neither translocation of PKC into the membrane fraction (Online Figure X) nor Akt phosphorylation, common mediators of ischemic preconditioning, was induced by overexpression of PKN in cardiac myocytes in vitro (Online Figure XI) . Thus, it is likely that the cardioprotective effects of CAPKN are mediated by PKC-and Akt-independent mechanisms. Development of small molecules that specifically stimulate PKN would be relevant clinically, considering the fact that stimulators of PKC have thus far shown promising results in their preclinical studies. 24 Tg-CAPKN mice showed mild LV hypertrophy. PKN is involved in actin reorganization in vascular smooth muscle cells 25 and stimulates atrial natriuretic factor gene expression in cardiac myocytes, 10 integral features of cardiac hypertrophy. PKN has also been shown to interact directly with ␣-actinin. 26 Thus, activation of PKN by stress could stimulate cardiac hypertrophy in vivo. It should be noted that whether or not PKN is a physiological mediator of cardiac hypertrophy requires further evaluation with loss-of-function models of PKN. The presence of hypertrophy alone may secondarily affect the cardioprotective effect of PKN against I/R. However, because even short-term activation or inactivation of PKN affects cell survival in a cell-autonomous manner, the protective effect of PKN may be, at least in part, hypertrophy-independent.
Thus far, we have found that LV function in Tg-CAPKN mice is well maintained, even after Ͼ1 year of follow up (data not shown). Together with the cardioprotective effect of PKN during I/R, we speculate that cardiac hypertrophy induced by PKN may be compensatory/physiological. However, this notion would require further testing by applying long-term hypertrophic stimulation, such as pressure overload, to Tg-CAPKN mice. In addition, the reduced heart rate could have resulted in a compensatory increase in ejection fraction, an index of LV contractility, in Tg-CAPKN mice. Thus, the effect of PKN on the intrinsic contractility of cardiac myocytes should be evaluated.
As noted above, PKN physically interacts with RhoA, 3 which positively regulates PKN. Transgenic mice with cardiac-specific overexpression of constitutively active RhoA exhibit early lethality, and those with overexpression of wild-type RhoA exhibit atrial enlargement, LV dilation, and contractile failure, with a markedly reduced heart rate. 27 The phenotype of Tg-CAPKN mice appears to be quite different from either of the above, suggesting that PKN may not be a major effector of RhoA in the heart. It should be noted, however, that Tg-CAPKN mice do show mild bradycardia. Because RhoA regulates the function of ion channels, such as Kir2.1 28 and L-type calcium channel, 29 PKN may participate in the regulation of ion channels by RhoA, thereby controlling heart rate.
␣BC, a member of the small heat shock protein and the molecular chaperone families, has protective effects against stresses. 12,30,31 Whereas some PKC isoforms phosphorylate ␣BC, 15 PKN upregulates mRNA expression of ␣BC through heat shock factor-1 in HeLa S3 cells. 13 Interestingly, although total expression of ␣BC did not differ between Tg-CAPKN and NTg hearts, both ␣BC phosphorylation at Ser59 and Ser45 and its expression in the cytoskeletal fraction were increased in Tg-CAPKN mice. Furthermore, I/R-induced increases in ␣BC phosphorylation at Ser59 and Ser45 were inhibited in Tg-DNPKN mice. These results are consistent with the notion that PKN plays an important role in mediating phosphorylation of ␣BC in response to I/R in the heart. Although phosphorylation of ␣BC at Ser59 can be mediated by activation of MAPKAPK-2, 32 MAPKAPK-2 is not activated in Tg-CAPKN mice (Online Figure XII) .
Although the specific role of PKN-induced Ser59 and Ser45 phosphorylation of ␣BC during I/R remains to be clarified, knockdown of ␣BC inhibited the protective effect of PKN in cardiac myocytes in response to H 2 O 2 , indicating that ␣BC mediates the cell-protective effect of PKN. Phosphorylation of ␣BC at the Ser59 residue contributes to cytoprotection in the heart, 12,32 primarily because of its association with cytoskeletal elements, where the chaperone stabilizes myofilament, thereby maintaining cellular integrity. 33, 34 Phosphorylation of ␣BC at either Ser59 or Ser45 stimulates its chaperone activity, 16 which in turn plays an important role in mediating cellular protein quality control through modulation of the ubiquitin-proteasome system and autophagy. These mechanisms of protein degradation act as defense mechanisms against unfolded proteins and are essential for cellular function and survival. 35 It has been shown that I/R decreases the proteasome activity but ischemic preconditioning improves the proteasomal activity after I/R and that increased proteasome activity is involved in the cardioprotective effect of preconditioning. 36 Interestingly, Tg-CAPKN mice showed enhanced proteasome activity both at baseline and after I/R, and epoxomicin treatment partially reversed the cardioprotective effect of PKN against I/R injury. Furthermore, decreases in the proteasome activity during I/R were significantly enhanced in the Tg-DNPKN heart. Thus, these results suggest that the increased proteasome activity, in part, mediates the cardioprotective effect of PKN.
In conclusion, PKN is activated by I/R and activation of PKN plays a cell-protective role in the heart in vivo. Furthermore, PKN mediates phosphorylation of ␣BC and stimulation of ubiquitin-proteasome activity, which, in part, mediates the protective effect of PKN in the heart (Online Figure XIII) . Thus, stimulation of PKN may represent a novel strategy for protecting the heart from I/R injury. 
Novelty and Significance
What Is Known?
• PKN is a serine/threonine kinase with a catalytic domain homologous to protein kinase C.
• PKN is activated by ischemia/reperfusion (I/R) in the retina and the brain in rats.
What New Information Does This Article Contribute?
• PKN is activated by ischemia (I) and reperfusion (R) in the heart and protects the heart against I/R injury.
• PKN phosphorylates ␣ B crystallin (␣BC) and stimulates proteasome activity, which plays an essential role in mediating the protective effect of PKN against I/R injury.
I/R in the heart causes myocardial injury and cardiac arrhythmia, which, in turn, induce LV dysfunction and/or cardiac death.
Identifying novel molecular mechanisms protecting the heart from I/R injury may lead to the development of new treatment for acute myocardial infarction. Here we show that PKN, a serine/ threonine kinase, is activated by both ischemia and reperfusion in the mouse heart. Activation of PKN promotes phosphorylation of ␣BC and stimulates ubiquitin-proteasome activity in the heart, which in turn plays an essential role in mediating the protective effect of PKN against myocardial I/R injury. Our study identifies PKN as a novel endogenous mediator of cardioprotection against I/R injury. PKN is unique in that chaperone-mediated activation of the proteasome plays an important role in mediating its cardioprotective action. We propose that stimulation of endogenous PKN could be a novel therapeutic strategy for limiting myocardial injury caused by acute I/R.
Supplemental data
Materials and Methods
Primary cultures of neonatal rat ventricular cardiac myocytes
Primary cultures of ventricular cardiac myocytes were prepared from 1-day-old Crl: (WI) BRWistar rats (Charles River Laboratories) as described previously 1 . A cardiac myocyte-rich fraction was obtained by centrifugation through a discontinuous Percoll gradient. Cells were cultured in complete medium (CM) containing Dulbecco's modified Eagle's medium (DMEM)/F-12 supplemented with 5% horse serum, 4 µg/ml transferrin, 0.7 ng/ml sodium selenite (Life Technologies, Inc.), 2 g/liter bovine serum albumin (fraction V), 3 mM pyruvic acid, 15 mM HEPES, 100 µM ascorbic acid, 100 µg/ml ampicillin, 5 µg/ml linoleic acid and 100 µM 5-bromo-2'-deoxyuridine (Sigma).
Construction of adenoviruses
Recombinant adenovirus vectors were constructed as described Ad-DNPKN). Adenovirus harboring beta-galactosidase (Ad-LacZ) was used as a control. In the in vitro study, transduction of full length PKN was used instead of CAPKN, because we were unable to generate adenovirus harboring CAPKN.
Echocardiography
Echocardiography was performed after mice were anesthetized with 12 μl/g body weight of 2.5% avertin as described previously 3 .
Ischemia/reperfusion
Pathogen-free mice were housed in a temperature-controlled environment with 12 hr light/dark cycles, where they received food and water ad libitum. Mice (3 months old) were anesthetized by intraperitoneal injection of pentobarbital sodium (60 mg/kg). A rodent ventilator (model 683;
Harvard Apparatus Inc) was used with 65% oxygen during the surgical procedure. The animals were kept warm using heat lamps and heating pads. Rectal temperature was monitored and maintained between 36.5 and 37.5°C. The chest was opened by a horizontal incision through the muscle between the ribs (third intercostal space). Ischemia was achieved by ligating the anterior descending branch of the left coronary artery (LAD) using an 8-0 nylon suture, with a 1 silicon tubing (1 mm OD) placed on top of the LAD, 2 mm below the border between left atrium and left ventricle (LV). Regional ischemia was confirmed by ECG change (ST elevation). After occlusion for 45 min, the silicon tubing was removed to achieve reperfusion. Treatment of mice with epoxomicin was conducted as described previously 4 . Treatment with propranolol, a beta adrenergic receptor antagonist, was conducted by intraperitoneal injection at a dose of 3 mg/kg five minutes before ischemia. For treatment with N-(2-mercaptopropionyl)-glycine (MPG), an antioxidant, MPG (100 mg/kg/hr) was infused intravenously through a cannula inserted into the jugular vein from15 min before ischemia throughout the experiment, as described previously 5, 6 .
Assessment of area at risk and infarct size
After I/R, the animals were reanesthetized and intubated, and the chest was opened. After arresting the heart at the diastolic phase by KCl injection, the ascending aorta was canulated and perfused with saline to wash out blood. The LAD was occluded with the same suture, which had been left at the site of the ligation. To demarcate the ischemic area at risk (AAR), Alcian blue dye (1%) was perfused into the aorta and coronary arteries. Hearts were excised, and LVs were sliced into 1-mm thick cross sections. The heart sections were then incubated with a 1% triphenyltetrazolium chloride (TTC) solution at 37°C for 10 min. The infarct area (pale), the AAR (not blue), and the total LV area from both sides of each section were measured using Adobe 
Evaluation of apoptosis in tissue sections
DNA fragmentation was detected in situ using the TUNEL assay as described previously 2 .
Briefly, deparaffinized sections were incubated with proteinase K, and DNA fragments were labeled with fluorescein-conjugated dUTP using TdT (Roche Molecular Biochemicals). Nuclear density was determined by manual counting of DAPI-stained nuclei in six fields for each animal using the 40x objective, and the number of TUNEL-positive nuclei was counted by examining the entire section using the same power objective.
Langendorff perfused hearts
Mice were anesthetized by intraperitoneal injection of pentobarbital sodium (60 mg/kg). Hearts 
Viability of the cells
Viability of the cells was measured by Cell Titer Blue (CTB) assays (Promega). In brief, cardiac myocytes (1 X10 5 per 100μl) were seeded onto 96-well dishes. After 24 hr, the medium was changed to serum free medium. Cardiac myocytes were transduced with adenovirus harboring PKN, DNPKN, or LacZ for 24 hours, or shRNA against PKN or control shRNA for 72 hours, and then treated with hydrogen peroxide for 8 hours. Viable cell numbers were measured by the CTB assay. The CTB assays were performed according to the supplier's protocol. The experiments were conducted in triplicate at least three times.
Analysis of DNA fragmentation by ELISA
Histone-associated DNA fragments were quantified using Cell Death Detection ELISA (Roche)
according to the manufacturer's protocol.
Immunoblot analysis
For immunoblot analysis, heart homogenates and cardiac myocyte lysates were prepared in For subcellular fractions, heart homogenates and cardiac myocyte lysates were prepared in Tris extraction buffer containing 20 mmol/L Tris·HCl (pH 7.5), 2 mmol/L Na 3 VO 4 , 1 mmol/L NaF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 50 µmol/LPMSF. The lysate was centrifuged at 3,000 g for 10 min at 4°C. The supernatant was used as the cytosolic fraction.
The pellet was resuspended in Tris-Triton buffer containing 10 mM Tris·HCl (pH 7.5), 100 mM NaCl, 20 mM Na 4 P 2 O 7 , 10% glycerol, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholate, 1 mM EDTA, 1 mM EGTA, 2 mM Na 3 VO 4 , 1 mM NaF, 50 μmol/L PMSF, 5 μg/ml aprotinin, and 5 μg/ml leupeptin, then centrifuged at 12,000 g for 20 min at 4°C. The supernatant was used as the cytoskeletal fraction. For preparation of the membrane fraction, the pellet from the cytosolic fraction was resuspended in the tissue sample buffer containing 0.5% NP-40, 0.1% deoxycholate, and 0.1% Brij 35, incubated on ice for 60 min, and recentrifuged at 10,000 rpm for 5 min. The supernatant was used as the membrane fraction 7 . These fractions were analyzed by immunoblot analysis with the use of appropriate antibodies. Densitometric analysis was performed using Scion Image software (Scion).
Proteasome assay
Tissue samples were homogenized in 50 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 5 mmol/L EDTA, and protease inhibitors. Cell debris was removed by centrifugation for 2 minutes at 12,000 g, and the supernatants were used for assay as described previously A) Phosphorylation of alpha B crystallin (BC) in the heart subjected to I/R is shown. B) The results of densitometric analysis of BC and Ser59 and Ser45 phosphorylated p-BC. Expression of total BC normalized with actin or p-BC normalized with total BC in sham-operated mouse hearts was set as 1. n=3 each. C）Cytoskeletal and cytosolic fractions were prepared from the hearts subjected to 45 min ischemia followed by 1 hr of reperfusion as described in the methods. Subcellular localization of p-BC (total, Ser45 or Ser59) in the heart subjected to 45 min ischemia followed by 1 hr reperfusion was evaluated by immunoblots. 
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